Browse our anti-LMO1 (LMO1) Antibodies

Full name:
anti-LIM Domain Only 1 Antibodies (LMO1)
On are 21 LIM Domain Only 1 (LMO1) Antibodies from 4 different suppliers available. A total of 22 LMO1 products are currently listed.
list all antibodies Gene Name GeneID UniProt
LMO1 245979  
LMO1 13162 Q61327
LMO1 6531 Q01959

Show all species

Show all synonyms

Most Popular Reactivities for anti-LMO1 (LMO1) Antibodies

Select your species and application

anti-Rat (Rattus) LMO1 Antibodies:

anti-Mouse (Murine) LMO1 Antibodies:

anti-Human LMO1 Antibodies:

All available anti-LMO1 Antibodies

Go to our pre-filtered search.

More Antibodies against LMO1 Interaction Partners

Mouse (Murine) LIM Domain Only 1 (LMO1) interaction partners

  1. An exquisite microanatomical regulation of dopamine by the dopamine transporter was identified in striosomes relative to the matrix in the corpus striatum.

  2. Data suggest that environment pollutants methylmercury and 1-methyl-4-phenylpyridinium decrease release of dopamine from dopaminergic neurons; this mechanism involves down-regulation of expression of Slc6a3 (show SLC6A3 Antibodies).

  3. This study show that Dopamine transporter is enriched in filopodia and induces filopodia formation.

  4. The sigma-1R deficiency through suppressing NR2B (show GRIN2B Antibodies) function and DAT (show SLC6A3 Antibodies) expression can reduce MPTP (show PTPN2 Antibodies)-induced death of dopaminergic neurons and parkinsonism.

  5. DAT (show SLC6A3 Antibodies) gene knockout in mice results dendritic spine loss in pyramidal neurons in the CA1 (show CA1 Antibodies) field of the hippocampus.

  6. Results show that moderate increases in DAT (show SLC6A3 Antibodies) function cause spontaneous dopaminergic cell loss, oxidative stress and fine motor impairment that is reversed by l-DOPA treatment

  7. Chronic and acute reductions of DAT (show SLC6A3 Antibodies) functioning in mice impaired decision-making.

  8. These results demonstrate that the presence of the N-terminal tag leads to impaired DAT (show SLC6A3 Antibodies) protein expression in vivo due in part to improper trafficking of the tagged transporter.

  9. studies demonstrate an in vivo functional impact of the DAT (show SLC6A3 Antibodies) Val559 variant, providing support for the ability of DAT (show SLC6A3 Antibodies) dysfunction to impact risk for mental illness.

  10. The data of this study imply that individual differences in DAT (show SLC6A3 Antibodies) expression (either genetically or pharmacologically induced) may affect susceptibility to addiction of different types of psychostimulants.

Human LIM Domain Only 1 (LMO1) interaction partners

  1. SLC6A3 gene may have a role in susceptibility to late-onset alcohol dependence in the Han Chinese population.

  2. This result suggests that persistent drug-induced parkinsonism in patients with visually normal DAT (show SLC6A3 Antibodies) imaging may be associated with subtle decrement of DAT (show SLC6A3 Antibodies) activity.

  3. the dopamine transporter SLC6A3 constitutes a novel biomarker that is highly specific for clear cell renal cell carcinoma

  4. Data suggest that variants rs28363170 and rs3836790 in the solute carrier family 6 member 3 gene are not associated with sporadic Parkinson's disease in Han Chinese population.

  5. Study systematically designed and characterized a set of 24 substrate-based bivalent ligands, and in combination with mutagenesis, induced-fit docking calculations, electrophysiology, and cysteine accessibility measurements; revealed novel insight into the molecular basis of substrate recognition in hSERT (show SLC6A4 Antibodies) and hDAT

  6. these findings provide compelling experimental evidence that DAT (show SLC6A3 Antibodies) N and C termini synergistically contribute to substrate and inhibitor affinities.

  7. these results are the first demonstration of pharmacological chaperoning of DAT (show SLC6A3 Antibodies) and suggest this may be a viable approach to increase DAT (show SLC6A3 Antibodies) levels in Dopamine Transporter Deficiency Syndrome and other conditions associated with reduced DAT (show SLC6A3 Antibodies) function.

  8. total of 1799 differentially methylated regions were identified including SLC6A3, Rab40C, ZNF584, and FOXD3 whose significant methylation differences were confirmed in breast cancer patients through quantitative real-time polymerase chain reaction.Methylation of those aforementioned genes in white blood cells of our young patients may highlight their potential as early epimarkers

  9. Data indicate genetic association between dopamine transporter SLC6A3 (DAT1) and hypertension, and the specific variable number tandem repeats (VNTR) alleles of SLC6A3 may be a risk factor for hypertension.

  10. The effects of parenting on self-control and offending are most pronounced for those who carry plasticity alleles for both MAOA (show MAOA Antibodies) and DAT1. Thus, MAOA (show MAOA Antibodies) and DAT1 may be implicated in offending because they increase the negative effects of parenting on self-control. Implications for theory are discussed.

LMO1 Antigen Profile

Antigen Summary

This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.

Alternative names and synonyms associated with LMO1

  • LIM domain only 1 (Lmo1) antibody
  • solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 (Slc6a3) antibody
  • solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) antibody
  • solute carrier family 6 (neurotransmitter transporter), member 3 (Slc6a3) antibody
  • DAT antibody
  • DAT1 antibody
  • Lmo3 antibody
  • PKDYS antibody

Protein level used designations for LMO1

LIM domain only protein 3 , LMO-3 , LIM domain only 3 , neuronal-specific transcription factor DAT1 , dopamine-inducible LIM-domain transcription factor DAT1 , DA transporter , dopamine transporter 1 , sodium-dependent dopamine transporter , solute carrier family 6 member 3 , solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 , DAT , solute carrier family 6, member 3

245979 Rattus norvegicus
13162 Mus musculus
6531 Homo sapiens
24898 Rattus norvegicus
Selected quality suppliers for anti-LMO1 (LMO1) Antibodies
Did you look for something else?